SUMMARY A controlled study compared 6 months' treatment of 60 patients with rheumatoid arthritis (RA). Halfwere randomly allocated to treatment with chloroquine 250 mg daily, the other half dapsone 100 mg daily (50 mg/day for the first 7 days) following a one-month run-in assessment period. All patients had active or progressing disease. Both treatment groups showed significant improvement in morning stiffness, number of painful joints, pain scores, Ritchie index, and proximal interphalangeal joint size, and the chloroquine group alone in grip strength. Laboratory tests showed significant decreases in erythrocyte sedimentation rate, C-reactive protein, and total serum protein levels, with significant increase in serum albumin in the dapsone group, where there was a significant mean drop in haemoglobin (< 1 g/dl) and a rise in serum bilirubin, associated with its haemolytic effect. X-ray erosion scores were not significantly affected. The clinical and laboratory responses became evident by the time of the 2-month assessment. Criteria for clinical and laboratory improvement were defined, according to which there were 21/26 improvers in the chloroquine group and 12/29 in the dapsone group. It is concluded that although both are effective preparations, chloroquine showed a significantly higher improvement rate and was certainly better tolerated. It is the preferred treatment for patients with active or progressive disease not controlled by nonsteroidal anti-inflammatory drugs, with dapsone as an alternative for patients who fail to respond to or cannot tolerate chloroquine. 
Patients and Methods
Patient selection and treatment allocation. All patients fulfilled the American Rheumatism Association criteria for probable, definite, or classical rheumatoid arthritis (RA). Exclusion criteria included administration of a disease-modifying drug within the previous 3 months and pregnancy. Admission criteria were failure to respond to NSAI drugs, or progression of disease as shown by increasing clinical, laboratory, or x-ray features, or 'new' patients showing poor prognostic features early in the disease-e.g., nodules, high latex titre, or early erosive changes. In both instances the judgement was essentially clinical. The only mandatory criteria were: (i) many painful joints (>6); (ii) high erythrocyte sedimentation rate (ESR) (>30 mm/h) and/or C-reactive protein (CRP) (>40 mg/l).
Allocation within the group was random, either chloroquine 250 mg daily or dapsone 50 mg daily for 1 week, then 100 mg daily. Routine nonsteroidal 200
anti-inflammatory agents, analgesics or medications for other diseases, were continued unaltered.
Assessment of treatment effect. Assessments were done 4 weeks before therapy was started (-4), the day it started (0), and then at months 2, 4, and 6, with additional laboratory tests at week -2 and the intermediate months. Latex and antinuclear factor (ANF) tests and x-rays were done initially and at 6 months.
Clinical assessments were of pain severity (0 to 4 and by visual analogue scale), duration (0 to 4) *One patient included in both criteria. Table 4 . Both treatment groups showed significant improvement in the majority of both subjective and objective indices. Although there was greater mean improvement in the chloroquine group for all except the mean number of painful joints, there were no significant differences between the groups. Laboratory indices ofdisease activity. As shown in tMean change per finger. There were no significant changes in mean values for total white cell or platelet counts or in alkaline phosphatase levels.
X-Rays. There were no clinically significant changes in the x-ray erosion scores.
Rate of response. The patients in both treatment groups showed steady and continuing clinical improvement over the 6-month observation period, already evident (particularly in the chloroquine group) by the time of the 2-month assessment.
The ESR and CRP values showed similar improvement. Haemoglobin increased slightly in the chloroquine group, but in the dapsone group showed a mean fall of more than 1 g/dl due to the haemolytic effect of dapsone, with gradual recovery therafter as the arthritis improved. Alkaline phosphatase was not significantly affected in either group.
When assessing these changes it should be noted that 5 patients were withdrawn from the dapsone group because of lack of response and 4 because of haemolytic anaemia, whereas none were for either reason in the chloroquine group.
Responses ofindividual patients. Improvement was categorised as clinical, laboratory, or both. Clinical improvement was a response in 2 of 4 features, with no worsening in the other 2, of a predetermined amount: morning stiffness, joint score, and Ritchie index by 50%; visual analogue scale score by 40%, with lesser amounts for those with low initial scores.
Laboratory improvement involved a decrease of at least 33% in either ESR or CRP, with no increase in either.
As shown in Table 6 , there were 8 patients in each group who showed clinical and laboratory improvement, but 13 in the chloroquine group compared with 4 in the dapsone group who showed clinical or laboratory improvement. The totals, 21/30 for chloroquine and 12/30 for dapsone, are significantly different (p<0 05).
Individual patient response to individual parameters. By plotting the initial score against the final with 12 and 3 in the chloroquine, 11 and 2 in the dapsone group respectively. The diagrams for the other disease features are similar, showing only small differences in effect between the 2 treatment groups (though it must be noted that 4 patients on dapsone were excluded from the 6 month analysis because of 'poor response'). The fall in CRP from high levels to within the normal range (<10 mg/l) in a large proportion of patients in both treatment groups is particularly well illustrated.
Discussion
Our study has certainly demonstrated that both substances effectively relieve the symptoms, clinical signs, and biological parameters of rheumatoid arthritis, with group responses being evident by 2 months and continuing up to 6 months. 
